Compare OMF & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMF | CYTK |
|---|---|---|
| Founded | 1920 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.0B |
| IPO Year | 2013 | 2004 |
| Metric | OMF | CYTK |
|---|---|---|
| Price | $64.06 | $63.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $68.23 | ★ $83.69 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | ★ 29.36 | N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $2,892,000,000.00 | $87,211,000.00 |
| Revenue This Year | $72.81 | $339.72 |
| Revenue Next Year | $8.39 | $79.08 |
| P/E Ratio | $10.77 | ★ N/A |
| Revenue Growth | 16.10 | ★ 2609.26 |
| 52 Week Low | $38.00 | $29.31 |
| 52 Week High | $71.93 | $70.98 |
| Indicator | OMF | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 50.19 |
| Support Level | $63.24 | $61.10 |
| Resistance Level | $71.93 | $65.35 |
| Average True Range (ATR) | 1.70 | 3.03 |
| MACD | -0.92 | 0.00 |
| Stochastic Oscillator | 8.98 | 58.49 |
OneMain Holdings Inc is a consumer finance company providing loan products to customers through its branch network and the internet. The company provides personal loan products; offers credit cards; offers optional credit insurance and others; offers a customer-focused financial wellness program, and acquisitions and dispositions of assets and businesses. It provides origination, underwriting, and servicing of personal loans to non-prime customers. The company's reportable segment is Consumer and Insurance. The main source of revenue is net interest income.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.